key: cord-0759752-a67hxixt authors: O Murchu, Eamon; Byrne, Paula; Walsh, Kieran A.; Carty, Paul G.; Connolly, Máire; De Gascun, Cillian; Jordan, Karen; Keoghan, Mary; O'Brien, Kirsty K.; O'Neill, Michelle; Smith, Susan M.; Teljeur, Conor; Ryan, Máirín; Harrington, Patricia title: Immune response following infection with SARS‐CoV‐2 and other coronaviruses: A rapid review date: 2020-09-23 journal: Rev Med Virol DOI: 10.1002/rmv.2162 sha: 31eb2cba6d4a7ec191b3f05ddc0934dfa6dbd209 doc_id: 759752 cord_uid: a67hxixt In this review, we systematically searched and summarized the evidence on the immune response and reinfection rate following SARS‐CoV‐2 infection. We also retrieved studies on SARS‐CoV and MERS‐CoV to assess the long‐term duration of antibody responses. A protocol based on Cochrane rapid review methodology was adhered to and databases were searched from 1/1/2000 until 26/5/2020. Of 4744 citations retrieved, 102 studies met our inclusion criteria. Seventy‐four studies were retrieved on SARS‐CoV‐2. While the rate and timing of IgM and IgG seroconversion were inconsistent across studies, most seroconverted for IgG within 2 weeks and 100% (N = 62) within 4 weeks. IgG was still detected at the end of follow‐up (49‐65 days) in all patients (N = 24). Neutralizing antibodies were detected in 92%‐100% of patients (up to 53 days). It is not clear if reinfection with SARS‐CoV‐2 is possible, with studies more suggestive of intermittent detection of residual RNA. Twenty‐five studies were retrieved on SARS‐CoV. In general, SARS‐CoV‐specific IgG was maintained for 1‐2 years post‐infection and declined thereafter, although one study detected IgG up to 12 years post‐infection. Neutralizing antibodies were detected up to 17 years in another study. Three studies on MERS‐CoV reported that IgG may be detected up to 2 years. In conclusion, limited early data suggest that most patients seroconvert for SARS‐CoV‐2‐specific IgG within 2 weeks. While the long‐term duration of antibody responses is unknown, evidence from SARS‐CoV studies suggest SARS‐CoV‐specific IgG is sustained for 1‐2 years and declines thereafter. In conclusion, limited early data suggest that most patients seroconvert for SARS-CoV-2-specific IgG within 2 weeks. While the long-term duration of antibody responses is unknown, evidence from SARS-CoV studies suggest SARS-CoV-specific IgG is sustained for 1-2 years and declines thereafter. A standardized protocol was adhered to 1 based on Cochrane rapid review methodology guidance. 2 Electronic databases (PubMed, EMBASE and EuropePMC) and pre-print servers (medRxiv, bioRxiv and Health Research Board [HRB] Open) were searched for the period 1 January 2000 until 26 May 2020. All potentially eligible papers, including non-peerreviewed pre-prints, were exported to Endnote X8.2 and screened for relevance. For each included study, data on the study design, participant demographics and clinically relevant data (such as the severity of initial infection) were extracted by two reviewers. As no universally accepted quality appraisal tool exists for many study designs included in this review, including for case series, a de-novo quality appraisal tool was developed, adapted from existing tools (such as the Newcastle-Ottowa scale 3 and the ROBINS-I tool 4 ). Supplementary Material 1 in Data S1 provides the full search strategy, inclusion criteria for the selection of studies and details of the quality appraisal tool used. The findings of the research question were synthesized narratively due to the heterogeneity of study designs and outcome data. The database search retrieved 4744 citations. Following removal of duplicates, 4119 unique citations were screened for relevance. Overall, 102 studies were identified that met our inclusion criteria, encompassing 6792 cases diagnosed by respiratory RT-PCR testing (SARS-CoV-2, SARS-CoV or MERS-CoV). These included 92 case series/cohort studies, 5-96 eight case reports [97] [98] [99] [100] [101] [102] [103] [104] and two crosssectional studies. 105 3.1 | Seroconversion rate and timing for SARS-CoV-2 In total, 43 studies were identified that assessed the rate and/or timing of seroconversion for IgM or IgG following acute SARS-CoV-2 infection. 7, [9] [10] [11] 18, 21, 23, 25, 26, [30] [31] [32] 34, 37, 39, 40, 43, 44, 46, 49, [60] [61] [62] 67, 68, 71, 73, 82, 86, 87, 90, 92, 94, 97, 98, 101, [104] [105] [106] [107] Up to 338 patients were enrolled in any single study 37 and the largest number of samples taken was 535. 90 The median age ranged from 37 106 to 68 years, 55 and a similar number of males and females were followed across studies. As SARS-CoV-2 was first identified in December 2019, there is a lack of evidence on the long-term duration of antibody responses following infection. Therefore, studies were also retrieved that investigated the long-term duration of immune responses to SARS-CoV and MERS-CoV. Eleven studies were identified that examined the duration of the By the end of follow-up, 92%-100% of patients had detectable neutralizing antibody levels. The duration of the immune response to SARS-CoV was investigated in 25 studies. 8 Three studies were identified that investigated the immune response associated with MERS-CoV infection, with the longest follow-up 24 months. One study (n = 9) reported a rigorous antibody response in all survivors who had severe disease, but not in survivors of mild disease. 6 Similar findings were reported in another study of 11 patients (five with severe disease and six with mild disease) who were followed up for 1 year. 19 5, 20, 35, 64, 68, 106 The association between lymphocyte counts (CD4 + and CD8 + subsets) and the severity of infection was investigated in two studies (N = 243 patients). 35, 57 In both, authors reported that CD4 + T cell and CD8 + T cell counts were significantly inversely associated with disease severity; the more serious the disease was, the lower were the T cell, CD4 + T cell and CD8 + T cell counts on admission. One study also measured the CD4 +/CD8 + ratio; all analyses indicated that the ratio was not significantly different between different conditions and outcomes. 57 The association between re-detection positive and severity of initial disease was investigated in two studies (N = 679 patients). 7, 41 Both studies found that mild or moderate cases were significantly more likely to re-present with detectable RNA by RT-PCR post-discharge compared with severe cases. Eleven studies provided a rate of re-detection via RT-PCR of respiratory samples in a cohort of recovered patients (defined as at least two RNA not detected samples for SARS-CoV-2 collected at ≥24-hour intervals). 17, 22, 33, 41, 71, 75, 76, 79, 81, 84 In these studies, the redetection rate ranged from 3% (2/62 cases) 79 to 31% (4/13 cases), 111 with the largest cohort reporting a re-detection rate of 17% (95% CI: 13%-20%; n = 69/414 cases). 41 Patients in whom SARS-CoV-2 RNA was re-detected were asymptomatic at the time of the positive re-detection test in all but two of the 19 studies. 17, 41 The first study reported that the majority of those in whom RNA was re-detected still had respiratory symptoms, including cough and increased sputum production on readmission. 41 3.9 | Methodological quality An agreed definition for reinfection (as opposed to re-detection) with SARS-CoV-2 was not identified, possibly due to the limited number of such events described in the literature. The overall quality of evidence was low due to the inherent bias associated with study designs. Concerns exist regarding the small sample size in many studies and the methodological quality of preprint studies that have not undergone a formal peer review process. While studies consistently demonstrated anti-SARS-CoV-2 IgG and neutralizing antibody detection beyond 2 weeks, limitations of this The levels of detection for SARS-CoV-2-specific antibodies were not uniform across studies, and frequently not reported. Differences This review was also limited by small sample size in a number of studies, although more recent studies typically included a larger number of participants with longer follow-up periods. Differences in the rate and timing of seroconversion, in particular, may become more consistent when studies that use validated tests on larger sample sizes are conducted. The evidence available to answer these research questions is evolving. While studies consistently found that all patients tested positive for IgG (and nearly all tested positive for neutralizing antibodies) beyond 4 weeks post-symptom onset, larger studies are necessary to validate these findings. While the role or duration of the antibody response following SARS-CoV-2 infection is unknown, all patients in reviewed studies maintained an IgG response at the longest follow-up (8 weeks post-infection). We hypothesize that this response may last much longer, as evidence from studies of SARS-CoV has shown that SARS-CoV-specific IgG is sustained for one to 2 years post-infection, with detection up to 12 years post-infection in one study. It is unclear if reinfection can occur following recovery from SARS-CoV-2, and the limited data to date are more suggestive of intermittent detection of inconsistently shed residual viral RNA. Limited evidence suggests that these individuals are not infectious to others. In the coming months, as the pandemic progresses, more evidence will emerge on the duration of immunity, pre-existing immunity due to crossprotection from seasonal coronaviruses, potential for re-infection and recurrent infectivity. Protocol for evidence synthesis support -COVID-19 Cochrane Rapid Reviews. Interim Guidance from the Cochrane Rapid Reviews Methods Group The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays. medRxiv Antibody response and disease severity in healthcare worker MERS survivors Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2 Case series of coronavirus (SARS-CoV-2) in a military recruit school: clinical, sanitary and logistical implications Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019 Disappearance of antibodies to SARS-associated coronavirus after recovery Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63 Longitudinal analysis of Severe Acute Respiratory Syndrome (SARS) coronavirus-specific antibody in SARS patients Response of memory CD8 + T cells to severe acute respiratory syndrome (SARS) coronavirus in recovered SARS patients and healthy individuals Clinical characteristics of re-hospitalized patients with COVID-19 in China Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity MERS-CoV antibody responses 1 year after symptom onset, South Korea Distinct early IgA profile may determine severity of COVID-19 symptoms: an immunological case series Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays Re-evaluation of retested nucleic acidpositive cases in recovered COVID-19 patients: report from a designated transfer hospital in Chongqing Early antibody response to SARS-CoV-2. medRxiv Characterization of anti-viral immunity in recovered individuals infected by SARS-CoV-2. medRxiv Detection of antibodies against SARS-CoV-2 in patients with COVID-19 Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France Virologic and clinical characteristics for prognosis of severe COVID-19: a retrospective observational study in Wuhan, China. medRxiv Letter to the Editor: Three cases of redetectable positive SARS-CoV-2 RNA in recovered COVID-19 patients with antibodies Detection of serum immunoglobulin M and immunoglobulin G antibodies in 2019-novel coronavirus infected cases from different stages SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors Profiling early humoral response to diagnose novel coronavirus disease (COVID-19) Long-term persistence of IgG antibodies in SARS-CoV infected healthcare workers COVID-19 in a patient with long-term use of glucocorticoids: a study of a familial cluster The clinical course and its correlated immune status in COVID-19 pneumonia Kinetics of severe acute respiratory syndrome (SARS) coronavirus-specific antibodies in 271 laboratoryconfirmed cases of SARS Detection of IgM and IgG antibodies in patients with coronavirus disease 2019 Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus The production of antibodies for SARS-CoV-2 and its clinical implication. medRxiv Long period dynamics of viral load and antibodies for SARS-CoV-2 infection: an observational cohort study Recurrence of SARS-CoV-2 PCR positivity in COVID-19 patients: a single center experience and potential implications Th2 predominance and CD8 + memory T cell depletion in patients with severe acute respiratory syndrome Clinical significance of IgM and IgG test for diagnosis of highly suspected COVID-19 infection Global profiling of SARS-CoV-2 specific IgG/IgM responses of convalescents using a proteome microarray Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019 Human neutralizing antibodies elicited by SARS-CoV-2 infection Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea Positive RT-PCR test results in patients recovered from COVID-19 Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients Profile of specific antibodies to the SARSassociated coronavirus Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus Protective effect of specific antibody in serum of convalescent patient with SARS Human CD4(+) memory T-lymphocyte responses to SARS coronavirus infection A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. medRxiv The comparative superiority of IgM-IgG antibody test to real-time reverse transcriptase PCR detection for SARS-CoV-2 infection diagnosis Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome Lymphocyte subset (CD4 +, CD8 +) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19 Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARSrecovered patients SARS-CoV-2 antibody responses do not predict COVID-19 disease severity Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients Lower detection rates of SARS-COV2 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19 Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients Recurrence of Positive SARS-CoV-2 Viral RNA in Recovered COVID-19 Patients during Medical Isolation Observation Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients Virological assessment of hospitalized patients with COVID-2019 Duration of antibody responses after severe acute respiratory syndrome Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: a descriptive study False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence Profile of specific antibodies to SARS-CoV-2: the first report Dynamic changes of T lymphocyte subsets in the long-term follow-up of severe acute respiratory syndrome patients Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus S antigen in recovered SARS patients Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation Evaluation of the auxiliary diagnostic value of antibody assays for the detection of novel coronavirus (SARS-CoV-2) Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients Recurrence of positive SARS-CoV-2 viral RNA in recovered COVID-19 patients during medical isolation observation Caution should be exercised for the detection of SARS-CoV-2, especially in the elderly Longitudinal change of severe acute respiratory syndrome coronavirus 2 antibodies in patients with coronavirus disease 2019 Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19 Virus shedding patterns in nasopharyngeal and fecal specimens of COVID-19 patients Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease Clinical and autoimmune characteristics of severe and critical cases of COVID-19 Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset Viral kinetics and antibody responses in patients with COVID-19 Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Natural course of severe acute respiratory syndrome-associated coronavirus immunoglobulin after infection Determining SARS sub-clinical infection: a longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland A case of COVID-19 and pneumonia returning from Macau in Taiwan: clinical course and anti-SARS-CoV-2 IgG dynamic Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of Lopinavir/Ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR Recurrence of COVID-19 after recovery: a case report from Italy on behalf of INMI and the Italian Army COVID-19 study groups. Coronavirus disease (COVID-19) in a paucisymptomatic patient: epidemiological and clinical challenge in settings with limited community transmission Positive result of Sars-Cov-2 in sputum from a cured patient with COVID-19 A Case Report of Moderate COVID-19 with an Extremely Long-Term Viral Shedding Period in China Early virus clearance and delayed antibody response in a case of COVID-19 with a history of co-infection with HIV-1 and HCV Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset. medRxiv A Case Report of Moderate COVID-19 with an Extremely Long-Term Viral Shedding Period in China Relationship of IgG antibody level and its duration with prognosis in convalescent patients with severe acute respiratory syndrome Study on the changing regularity of special antibody and expression of stomach and enteric involvement on SARS-coronavirus infection in the recovery period of severe acute respiratory syndrome Positive result of Sars-Cov-2 in faeces and sputum from discharged patient with COVID-19 in Yiwu Chinese National Health Commission (translated by the Chinese Society of Cardiology) COVID-19, SARS and MERS: are they closely related? Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19) SARS-CoV-2 viral load in upper respiratory specimens of infected patients Findings from investigation and analysis of re-positive cases The National Institute for Biological Standards and Control (NIBSC) COVID-19)-related research reagents International reference standards: antibody standards for the indirect enzyme-linked immunosorbent assay Rapid health technology assessment of alternative diagnostic testing approaches for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Covid-19: "unacceptable" that antibody test claims cannot be scrutinised, say experts Interim guidelines for COVID-19 antibody testing in clinical and public health settings The authors would like to thank Executive Assistant Debra Spillane (HIQA) and Information Specialist Paul Murphy (RCSI). The authors have no competing interest. Additional supporting information may be found online in the Supporting Information section at the end of this article.